Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more
Chimeric Therapeutics Limited (CHMMF) - Total Assets
Latest total assets as of June 2025: $21.57 Million USD
Based on the latest financial reports, Chimeric Therapeutics Limited (CHMMF) holds total assets worth $21.57 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chimeric Therapeutics Limited - Total Assets Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chimeric Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Chimeric Therapeutics Limited's total assets of $21.57 Million consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.7% |
| Accounts Receivable | $4.55 Million | 21.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.04 Million | 51.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chimeric Therapeutics Limited's current assets represent 48.8% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2025, down from 100.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, a decrease from 13826165.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 51.2% of total assets.
Chimeric Therapeutics Limited Competitors by Total Assets
Key competitors of Chimeric Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Chimeric Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Chimeric Therapeutics Limited generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Chimeric Therapeutics Limited is currently not profitable relative to its asset base.
Chimeric Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.72 | 0.24 | 0.00 |
| Quick Ratio | 0.72 | 0.24 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.09 Million | $ -10.47 Million | $ -63.91K |
Chimeric Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Chimeric Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 41.2% |
| Total Assets | $21.57 Million |
| Market Capitalization | $2.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chimeric Therapeutics Limited's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chimeric Therapeutics Limited's assets grew by 41.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chimeric Therapeutics Limited (2020–2025)
The table below shows the annual total assets of Chimeric Therapeutics Limited from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $21.57 Million | +41.24% |
| 2024-06-30 | $15.27 Million | -31.74% |
| 2023-06-30 | $22.38 Million | -35.85% |
| 2022-06-30 | $34.88 Million | -4.45% |
| 2021-06-30 | $36.50 Million | +36504760.00% |
| 2020-06-30 | $100.00 | -- |